Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women

Ju Yeon Moon, Eun Jig Lee, Woong Youn Chung, Myeong Hee Moon, Bong Chul Chung, Man Ho Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Estrogen metabolism may be associated with the pathophysiological development of papillary thyroid carcinoma (PTC). Methods. To evaluate the differential estrogen metabolism between benign and malignant PTCs, estrogen profiling by gas chromatography-mass spectrometry was applied to urine samples from postmenopausal patients with 9 benign tumors and 18 malignant stage I and III/IV PTCs. Results: The urinary concentration of 2-methoxyestradiol was significantly lower in the stage I malignant patients (3.5-fold; P < 0.025) than in the benign group. The metabolic ratios of 16α-OH-estrone/estrone and estriol/estradiol, which are responsible for 16α-hydroxylase activity, were increased more than 2.5-fold in the advanced-stage malignant PTC (P < 0.02 each). The more than 6.2-fold decrease in the urinary 2-/16α-hydroxylase ratio in stage III/IV malignant PTC was consistent with the ratio in postmenopausal patients with endocrine gland cancers. In addition, reductive 17β-hydroxysteroid dehydrogenase (17β-HSD; estradiol/estrone or estriol/16α-OH-estrone) was present at significantly higher levels in subjects with stage III/IV malignant PTCs than in benign subjects (>3.5-fold difference; P < 0.002). In particular, the estriol/16α-OH-estrone ratio differentiated between the benign and early-stage malignant patients (P < 0.01). Conclusions: Increased 16α-hydroxylation and/or a decreased 2-/16α-ratio, as well increased reductive 17β-HSD, with regard to estrogen metabolism could provide potential biomarkers. The devised profiles could be useful for differentiating malignant thyroid carcinomas from benign adenomas in postmenopausal women.

Original languageEnglish
Article number25
JournalBMC Clinical Pathology
Volume13
Issue number1
DOIs
Publication statusPublished - 2013 Oct 29

Fingerprint

Thyroid Gland
Estrogens
Factor IX
Neoplasms
Estriol
Estrone
Hydroxylation
Thyroid Neoplasms
Adenoma
Gas Chromatography-Mass Spectrometry
Biomarkers
Urine

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Cite this

@article{aea095b25ac14aaaa4b619f51d117624,
title = "Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women",
abstract = "Background: Estrogen metabolism may be associated with the pathophysiological development of papillary thyroid carcinoma (PTC). Methods. To evaluate the differential estrogen metabolism between benign and malignant PTCs, estrogen profiling by gas chromatography-mass spectrometry was applied to urine samples from postmenopausal patients with 9 benign tumors and 18 malignant stage I and III/IV PTCs. Results: The urinary concentration of 2-methoxyestradiol was significantly lower in the stage I malignant patients (3.5-fold; P < 0.025) than in the benign group. The metabolic ratios of 16α-OH-estrone/estrone and estriol/estradiol, which are responsible for 16α-hydroxylase activity, were increased more than 2.5-fold in the advanced-stage malignant PTC (P < 0.02 each). The more than 6.2-fold decrease in the urinary 2-/16α-hydroxylase ratio in stage III/IV malignant PTC was consistent with the ratio in postmenopausal patients with endocrine gland cancers. In addition, reductive 17β-hydroxysteroid dehydrogenase (17β-HSD; estradiol/estrone or estriol/16α-OH-estrone) was present at significantly higher levels in subjects with stage III/IV malignant PTCs than in benign subjects (>3.5-fold difference; P < 0.002). In particular, the estriol/16α-OH-estrone ratio differentiated between the benign and early-stage malignant patients (P < 0.01). Conclusions: Increased 16α-hydroxylation and/or a decreased 2-/16α-ratio, as well increased reductive 17β-HSD, with regard to estrogen metabolism could provide potential biomarkers. The devised profiles could be useful for differentiating malignant thyroid carcinomas from benign adenomas in postmenopausal women.",
author = "Moon, {Ju Yeon} and Lee, {Eun Jig} and Chung, {Woong Youn} and Moon, {Myeong Hee} and Chung, {Bong Chul} and Choi, {Man Ho}",
year = "2013",
month = "10",
day = "29",
doi = "10.1186/1472-6890-13-25",
language = "English",
volume = "13",
journal = "BMC Clinical Pathology",
issn = "1472-6890",
publisher = "BioMed Central",
number = "1",

}

Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women. / Moon, Ju Yeon; Lee, Eun Jig; Chung, Woong Youn; Moon, Myeong Hee; Chung, Bong Chul; Choi, Man Ho.

In: BMC Clinical Pathology, Vol. 13, No. 1, 25, 29.10.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women

AU - Moon, Ju Yeon

AU - Lee, Eun Jig

AU - Chung, Woong Youn

AU - Moon, Myeong Hee

AU - Chung, Bong Chul

AU - Choi, Man Ho

PY - 2013/10/29

Y1 - 2013/10/29

N2 - Background: Estrogen metabolism may be associated with the pathophysiological development of papillary thyroid carcinoma (PTC). Methods. To evaluate the differential estrogen metabolism between benign and malignant PTCs, estrogen profiling by gas chromatography-mass spectrometry was applied to urine samples from postmenopausal patients with 9 benign tumors and 18 malignant stage I and III/IV PTCs. Results: The urinary concentration of 2-methoxyestradiol was significantly lower in the stage I malignant patients (3.5-fold; P < 0.025) than in the benign group. The metabolic ratios of 16α-OH-estrone/estrone and estriol/estradiol, which are responsible for 16α-hydroxylase activity, were increased more than 2.5-fold in the advanced-stage malignant PTC (P < 0.02 each). The more than 6.2-fold decrease in the urinary 2-/16α-hydroxylase ratio in stage III/IV malignant PTC was consistent with the ratio in postmenopausal patients with endocrine gland cancers. In addition, reductive 17β-hydroxysteroid dehydrogenase (17β-HSD; estradiol/estrone or estriol/16α-OH-estrone) was present at significantly higher levels in subjects with stage III/IV malignant PTCs than in benign subjects (>3.5-fold difference; P < 0.002). In particular, the estriol/16α-OH-estrone ratio differentiated between the benign and early-stage malignant patients (P < 0.01). Conclusions: Increased 16α-hydroxylation and/or a decreased 2-/16α-ratio, as well increased reductive 17β-HSD, with regard to estrogen metabolism could provide potential biomarkers. The devised profiles could be useful for differentiating malignant thyroid carcinomas from benign adenomas in postmenopausal women.

AB - Background: Estrogen metabolism may be associated with the pathophysiological development of papillary thyroid carcinoma (PTC). Methods. To evaluate the differential estrogen metabolism between benign and malignant PTCs, estrogen profiling by gas chromatography-mass spectrometry was applied to urine samples from postmenopausal patients with 9 benign tumors and 18 malignant stage I and III/IV PTCs. Results: The urinary concentration of 2-methoxyestradiol was significantly lower in the stage I malignant patients (3.5-fold; P < 0.025) than in the benign group. The metabolic ratios of 16α-OH-estrone/estrone and estriol/estradiol, which are responsible for 16α-hydroxylase activity, were increased more than 2.5-fold in the advanced-stage malignant PTC (P < 0.02 each). The more than 6.2-fold decrease in the urinary 2-/16α-hydroxylase ratio in stage III/IV malignant PTC was consistent with the ratio in postmenopausal patients with endocrine gland cancers. In addition, reductive 17β-hydroxysteroid dehydrogenase (17β-HSD; estradiol/estrone or estriol/16α-OH-estrone) was present at significantly higher levels in subjects with stage III/IV malignant PTCs than in benign subjects (>3.5-fold difference; P < 0.002). In particular, the estriol/16α-OH-estrone ratio differentiated between the benign and early-stage malignant patients (P < 0.01). Conclusions: Increased 16α-hydroxylation and/or a decreased 2-/16α-ratio, as well increased reductive 17β-HSD, with regard to estrogen metabolism could provide potential biomarkers. The devised profiles could be useful for differentiating malignant thyroid carcinomas from benign adenomas in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=84886187680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886187680&partnerID=8YFLogxK

U2 - 10.1186/1472-6890-13-25

DO - 10.1186/1472-6890-13-25

M3 - Article

AN - SCOPUS:84886187680

VL - 13

JO - BMC Clinical Pathology

JF - BMC Clinical Pathology

SN - 1472-6890

IS - 1

M1 - 25

ER -